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Abstract: 
TRAF-interacting protein (TRIP) is a ubiquitously expressed nucleolar E3 ubiquitin 
ligase. Ubiquitination of proteins is a post-translational modification, which decides on 
the cellular fate of the protein. TRIP in vivo substrate has not been yet identified. 
However, TRIP has been shown to play an important role in cellular proliferation, 
especially in keratinocytes. TRIP was found to be up-regulated in basal cell carcinoma 
(BCC) at the mRNA level. This prompted us to elucidate its role in skin proliferative 
diseases such as cancer by analyzing its expression in BCCs at protein level and in 
squamous cell carcinoma (SCC) at mRNA and protein level. To that purpose, we 
performed a real-time PCR (qPCR) analysis followed by an immunohistochemistry 
(IHC) on formalin-fixed, paraffin-embedded (FFPE) biopsies. 
The real-time PCR was performed on 12 RNA samples of which 6 were extracted from 
SCC biopsies and 6 from normal human skin. The results were statistically insignificant. 
Further analyses are needed on new RNA samples.  
The IHC assay was performed on 20 biopsies from BCCs, 21 biopsies from SCCs and 
on 5 tissues from normal human skin. The results obtained showed an extensive 
expression of TRIP in keratinocytes nuclei. Due to various limitations related to the 
technique and to doubts about preservation of the antigens in the tissues from normal 
human skin, we could not highlight a clear difference in TRIP expression between the 
different tissues. 
In conclusion, further analyses are needed on new RNA samples (qPCR) and on better 
preserved FFPE tissues from normal skin (IHC) to assess TRIP relative expression in 
BCCs and SCCs versus normal human skin. 
Keywords: TRAF-interacting protein, TRIP, basal cell carcinoma, squamous cell 
carcinoma. 
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1 INTRODUCTION 
1.1 TRAF-interacting protein 
TRAF-interacting protein (TRIP) was initially identified to interact with Tumor Necrosis Factor 
Receptor –associated Factors (TRAF1 and TRAF2), and was reported to inhibit NF-kB 
activation. Analysis of TRIP sequence revealed that TRIP is composed of an N-terminal RING 
finger motif, followed by coiled-coil and leucine zipper domains, both of which are implicated in 
protein-protein interactions (1). Subsequently, a study demonstrated that TRIP is a RING 
dependent E3 ubiquitin ligase which is able to undergo auto-ubiquitination (2).  
E3 ligases carry out the final step in the ubiquitination cascade, catalyzing transfer of ubiquitin 
from an E2 enzyme to substrate (3). Ubiquitination is mostly known as a signal for proteasomal 
degradation but is also a signal for other cell processes such as DNA reparation, chromatin 
remodeling and cell signaling (4). The deregulation of several E3 ligases (such as BRCA 1, 
Mdm2, COP1) is known to be implicated in cancer development (5).  
TRIP potential substrates are unknown (6). However, recent data showed that TRIP promotes 
ubiquitination of DNA polymerase η in humans cells and in Drosophila embryos which 
positively regulates this polymerase activity, suggesting that TRIP promotes proper cell cycle 
progression (7). Another potential substrate of TRIP is the TANK-binding kinase 1, whose 
proteasomal degradation is promoted by TRIP, therefore inhibiting IFN-beta signaling and the 
antiviral response (8). 
 
Nopo is the Drosophila homolog of human TRIP. The alteration of its RING domain showed a 
lethal effect on Drosophila embryos, due to spindle defects, suggesting a role of Nopo in 
preservation of the integrity of the genomic integrity during early embryogenesis (9). Similarly, 
an attempt to generate TRIP knockout mice resulted in death of the animals during the 
embryonic development due to proliferation defects and excessive cell apoptosis (10). In 
human cells, TRIP E3 ligase activity was found to be functionally required for the spindle  
assembly checkpoint control (11). 
 
Moreover, TRIP has been identified as interactor of CYLD through the C-terminal part of TRIP 
(12). CYLD is a tumor suppressor gene whose mutation is associated with familial 
cylindromatosis, a condition leading to the development of multiple skin appendages tumors 
(13). CYLD expression was found to be strongly down regulated in basal cell carcinoma (14). 
CYLD is a de-ubiquitinase that down regulates NF-kB signaling (12), one consequence of this 
being the prevention of the transcription of cyclin D1 and, thus, inhibiting cell proliferation in 
keratinocytes (15). In human keratinocytes, CYLD over-expression increases epidermal 
differentiation and has the ability to decrease non-melanoma skin cancer progression and 
aggressiveness (16).  
 
The tyrosine kinase SYK, a tumor suppressor, was also identified as a TRIP interactor. In 
breast epithelial cells, it has been shown that SYK and TRIP have opposing functions in the 
regulation of NF-kB activity (17). 
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TRIP mRNA is expressed at low levels in a large number of mouse tissues (6). In human 
keratinocytes, TRIP mRNA expression levels are high in proliferating but low in differentiating 
cells (10). This has been shown to be regulated by PKC and the PI3K-Akt-mTOR pathway, 
both having an effect on the E2F family of transcription factors. In addition, knockdown of TRIP 
reduced proliferation rate of human keratinocytes and promoted the expression of 
differentiation markers such as keratin 1 and profilaggrin. Interestingly, these effects were not 
the result of an increased NF-kB activity. Concerning other cells types, TRIP expression was 
found to be down regulated during the late stages of osteoclastogenesis (2). In human 
disease, TRIP level of expression was found to be increased in basal cell carcinoma (10). This 
expression level has not been studied in other types of skin tumors. 
1.2 Basal cell carcinoma 
Basal cell carcinoma (BCC) is the most common malignant cancer in individuals of mixed 
European descent. Its incidence is increasing due to aging of the population and sun exposure 
habits. BCC can be locally aggressive but does not normally metastasize (18).   
 
BCCs display 5 major histological patterns: nodular, superficial, micronodular, infiltrating and 
sclerosing (=morpheic) which have different medical prognosis. Nodular and superficial BCCs 
can be removed by simple surgical excision in a high percentage of cases whereas the 
micronodular, the infiltrating and the sclerosing act more aggressive and have a higher risk of 
incomplete surgical removal (19). 
 
Aberrant activation of the Sonic Hedghog signaling pathway plays a key role in the 
development of all types of BCC (18). The molecular pathogenesis leading to the different 
histological patterns of BCC is not well understood. Some data suggest that the magnitude of 
the Hedghog pathway activation may play a role for the tumor phenotype (20). Differences 
were found between the BCC types in expression level of different genes like nMyc (21) or 
genes associated with the MAP kinase pathway (22). 
 
TRIP was found to be up regulated in BCC at the mRNA level (10), however its expression at 
protein level was never assessed. 
1.3 Cutaneous squamous cell carcinoma 
Cutaneous squamous cell carcinoma (SCC) is the second most common human cancer. The 
evolution of SCC is a process ranging from the precursor actinic keratosis to the SCC in situ, 
also called Bowen disease, invasive SCC and finally metastatic SCC (23). Histologically, the 
invasive SCC can be divided into three categories: the well, medium and poorly differentiated. 
Low degree of differentiation is associated to a higher risk of metastasis (24).  
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Unlike BCC, SCC pathogenesis is not associated with a specific signaling pathway. P53 
mutations are found in 40% of SCCs. Aberrant activation of EGFR and Fyn are commonly 
found as well as activating mutations of the Ras oncogene (23). 
 
TRIP expression in SCC is unknown. 
1.4 Aims of this work 
As TRIP seems to be implicated in cell proliferation and differentiation, especially in 
keratinocytes, a dysfunction in its expression could play a role in proliferative skin diseases 
such as cancer (10). An analysis of its expression in different skin tumors will help to 
understand the biological function of TRIP and its possible role in tumor genesis. 
 
Regarding the fact that TRIP expression has not been analyzed in skin cancer types other than 
the basal cell carcinoma at mRNA level, the aim of this work is to analyze TRIP mRNA and 
protein level in biopsies from SCC and protein level in BCC. In order to do so, the chosen 
method was real-time PCR analysis followed by an immunohistochemistry on formalin-fixed, 
paraffin-embedded tumor tissues. 
 
Considering that TRIP is down regulated during epidermal differentiation and that its 
knockdown repressed keratinocyte proliferation and enhanced differentiation, an expected 
result of this work could be the increased expression of TRIP in skin tumors. This is also 
consistent with the data showing the increased expression of TRIP at mRNA level in basal cell 
carcinoma (10). 
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2 RESULTS 
2.1 Real-time PCR 
The aim of this experiment was to measure TRIP relative expression at mRNA level in SCC 
versus normal human skin.  
 
To that purpose, we used 12 total RNA samples of which 6 were extracted from SCC biopsies 
(sample 1 to 6) and 6 from normal human skin (sample 7 to 12). 
 
The RNA samples were first reverse transcribed into cDNA. The cDNA was then analyzed in 
duplicate by real-time PCR. The target was TRIP and two housekeeping/normalizer genes, 
rpl13A and Tbp (endogenous control). 
 
All the primers used in this experiment span exon-exon junctions in the target mRNA (=cross-
intron primers) to prevent amplification of possible genomic DNA.  
 
The results are shown in figure 1, following a comparative CT method, the 2–ΔCt method (25). 
Statistical significance was calculated using students t-test. 
 
For the 2–ΔCt method to be valid, the amplification efficiencies of the target and the 
housekeeping gene must be approximately equal (25). If efficiencies are dissimilar, the ratio in 
Ct values of the target and the housekeeping gene will not be constant when the template 
amounts are varied. This assessment was already done for the need of other works in the 
laboratory.  
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This experiment shows a fold change in TRIP expression of -2.83 in SCC versus NHS using 
the RPL13 normalizer gene and of – 3.63 using the TBP normalizer gene. However, the 
Student’s t-test is statistically insignificant in both cases (p>0.05).  
 
The use of cross-intron primers do not provide full protection against amplification of 
contaminating genomic DNA. Considering the possibility of such a contamination, the RNA 
samples were treated by DNAse digestion. After this digestion, RNA concentration was 
measured by NanoDrop, revealing very low concentration in some samples. RNA was reverse 
transcribed into cDNA. Several qPCR were performed using RPL13, TBP and RPL0 as 
normalizer genes (Figure 2).  
 
 
 
Figure 1 - TRIP with RPL13 (A) and TBP (B) as normalizer genes – No template control (NTC) contains all 
the real-time PCR components except the cDNA, allowing the detection of contaminating nucleic acids. 
 
 
  9 
 
 
 
The results we find in figure 2 are again statistically non significant. Due to big 2-ΔCt variations 
in some samples, it was difficult to display the results in a graph in a readable manner. 
 
As we can see, fold changes in TRIP expression vary depending on the housekeeping gene 
used.  
The expression of housekeeping genes is presumed to be stable within the samples extracted 
from SCCs and normal skin tissues. 
 
Figure 2 – postDNAse digestion – TRIP with RPL13 (C), TBP (D) and RPL0 (E) as normilizer genes. 
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RPL13A, TBP and RPLO are all housekeeping genes who are commonly used in studies of 
gene expression in keratinocytes (26). However, no universal housekeeping gene with proven 
invariable expression between experimental conditions has been yet identified (27). Therefore, 
the validity of a housekeeping gene should be evaluated before analysis of expression of other 
gene. This was not done in this experiment. Hence, we cannot exclude that the results found in 
this experiment were biased by the fact that the expression of the housekeeping genes used 
here were not stable between the different mRNA samples, especially in the ones extracted 
from SCC. 
 
Moreover, we cannot assure that the SCC biopsies from which the RNA was extracted did 
contain a high proportion of tumor tissue. Indeed, tumors can be histologically very 
heterogeneous and contain large amount of non tumoral tissue, like immune cells. Unlike 
BCCs, SCCs do not have a known quantifiable marker that we could have use as a control. 
 
Furthermore, we cannot exclude a partial degradation of the RNA samples during the DNAse 
digestion process. Indeed, concentration of nucleic acids in some samples was very low after 
this process and sample 6 could not be amplified anymore.  
 
Therefore, relative quantification of TRIP mRNA in SCC could not be determined by this 
experiment.  
2.2 Immunohistology 
Evaluation of gene expression at mRNA level is a vital initial step but is insufficient. Studies 
have shown that there is often discordance between levels of nucleic acids and proteins, 
implying that the study of both measures is important (28). Immunohistochemistry (IHC) on 
formalin-fixed, paraffin-embedded (FFPE) tissue is a widely used technique to assess protein 
expression. It allows preservation of morphology of tissues. FFPE are easy to store, can be 
conserved over a long time and can therefore be easily obtained for a study.  
However, the limitations of IHC are numerous. It involves a series of steps which can all affect 
the reliability of the results. 
2.2.1 Antibody validation 
Before the IHC can be started, the first critical step is to determine the validity of the antibody 
designed for the experiment. 
 
To be validated, an antibody needs to recognize the antigen of interest in a specific and 
reproducible manner (29). 
 
We had two anti-TRIP antibodies that were candidates for the IHC experiment, the Abcam ab 
151307 (next rabbit anti-TRIP) and the Abcam ab 4533 (next goat anti-TRIP). Both are 
polyclonal antibodies. The rabbit anti-TRIP is generated against a recombinant fragment of 
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TRIP and the goat anti-TRIP against a synthetic peptide. To determine the specificity of those 
antibodies, we performed a Western Blot, followed by an immunofluorescence on cultured 
cells lines. 
 
Antibody reproducibility means good correlation between different antibody lots. Different lots 
can show different staining patterns (29). The question of reproducibility was not tested in this 
work as we did only use one lot of each antibody.  
2.2.1.1 Western Blot 
7 cultures of 293 T cells (human embryonic kidney) were transfected with several plasmids 
using the CaCl transfection method according to the next table: 
 
Table 1 (ug/ul DNA) 
Plasmid 1 2 3 4 5 6 7 
pmycTRIP 2.4 2.4 2.4 2.4 2.4 2.4 2.4 
MT742  1.2   2.4   
MT743   1.5   3  
pSHC2    1.95   3.9 
pGEM-11Zf+ 2 1 1 1    
pEGF-N3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
 
The 7 cultures were transfected with plasmids containing TRIP attached to a Myc tag. A 
plasmid containing a fluorescent tag pEGF-N3 was also transfected to each culture. 
 
MT742 and MT743 are both shRNAs targeting TRIP. pSHC2 is the negative control of MT742 
and MT743. pGEM-11Zf+ is a standard cloning vector.  
 
 
As we can see, the transfection was successful in all cultures. The differences in protein 
quantity may be due to loading irregularity or variances in transfection efficiency between the 7 
cultures. Ideally, a homogenously expressed gene like actin should have been used as a 
loading control. 
 
 
Figure 3: anti-GFP 
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TRIP is a 53 kDa protein. In figure 4, two lines can be seen between the 50 kDa and the 75 
kDa markers. Cultures 2, 3, 5 and 6 are expected to express less TRIP because there were 
transfected with inhibitors. This pattern is observed in the line underneath. The line above may 
be due to unspecific binding of the antibody or to its binding to an ubiquitinated TRIP. 
 
 
Figure 5 shows one line above the 50 kDa marker, suggesting a specific binding of the goat 
antibody to TRIP protein. 
  
 
 
Figure 4: rabbit anti-TRIP 
 
Figure 5: goat anti-TRIP 
 
Figure 6: anti-Myc 
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Figure 6 shows the positive control using a specific anti-myc antibody which makes the tag 
attached to TRIP apparent. The second line seen in figure 2 cannot be found here. It could be 
caused by post-translational modifications or degradation of TRIP which make the Myc-Tag 
unrecognizable. However, we cannot exclude an unspecific binding of the rabbit anti-TRIP with 
this experiment. 
 
Furthermore, the two antibodies we tested were generated against a synthetic 
peptide/recombinant fragment of TRIP and not against a purified protein. Those 
peptides/recombinants do not necessarily recognize the 3D structure or the post-translational 
modifications of the native protein (29). Therefore, the tested antibodies may bind to the 
denatured TRIP in the WB but not to the native conformation of TRIP that is found in fixed 
tissues. 
2.2.1.2 Immunofluorescence 
As we saw, a WB is not a sufficient test to validate an antibody designed to bind to an IHC 
because of the denaturation of the antigens. Therefore, an immunofluorescence (IF) may be 
useful to investigate the specificity further. 
 
In this experiment, we transfected 3 HeLa cells cultures with a plasmid containing TRIP 
attached to a FLAG-tag. After two days of growth, the cultured cells were fixed in 
paraformaldehyde and an IF was performed using DAPI for fluorescent staining of the DNA. 
During the IF, the 3 cultures were incubated each with another primary antibody: one with the 
rabbit anti-TRIP, one with the goat anti-TRIP and one with a rabbit anti-FLAG.  
 
Unfortunately, the cells incubated with the goat anti-TRIP and the anti-FLAG tag were probably 
degraded during the fixing process and the results of the IF were non interpretable in both 
cases. 
 
In Figure 7 and 8, we can see the results for the culture incubated with the rabbit anti-TRIP. 
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The blue signal emitted by DAPI highlights the nucleus. The red signal shows indirectly the 
rabbit anti-TRIP. As we can see in figure 7, the blue and the red signals are perfectly 
superimposed which implies that the rabbit anti-TRIP reacts with an antigen located in the 
nucleus. 
 
Figure 8 is the negative control where the cells were only incubated with the secondary 
antibody but not with the rabbit anti-TRIP. As expected, there’s no red signal. 
 
TRIP is a protein known to be located in the nucleus (11). We demonstrate here that the rabbit 
anti-TRIP detects a nuclear antigen which may assist the specificity of the antibody. 
 
Unfortunately the culture incubated with the anti-FLAG tag (attached to TRIP) was degraded 
and could not be interpreted. Therefore, a control is lacking to investigate if the FLAG tag and 
the TRIP signal have similar cellular location, which would be a further argument in favor of the 
rabbit anti-TRIP specificity. 
 
 
Figure 7: rabbit anti-TRIP 1:300 
 
Figure 8: rabbit anti-TRIP - negative control (no primary antibody) 
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After this experiment, it was decided to choose the rabbit anti-TRIP for the 
immunohistochemistry on FFPE tumor tissue.  
2.2.2 Immunohistochemistry 
 
To continue the analysis of the expression of TRIP protein, we decided to perform IHC to 4 
different types of BCC: the infiltrating (INF), nodular (NOD), superficial (SUP) and sclerosing 
(SCL) types. 
 
Concerning the SCC, we divided the biopsies into four categories: the Bowen disease, the 
well- (BD), the medium- (MD) and the poorly- (PD) differentiated. 
 
The classification of the biopsies between the different categories was based on the medical 
pathological reports of the hospital department of dermatology of the CHUV. 
 
Initially we had the following biopsies available which we cut into 5 µm sections: 
 
Table 2 – number of biopsies for the IHC 
BCC biopsies 
  INF NOD SCL SUP 
Ordered 5 6 6 7 
Excluded 1 2 1 0 
Total 4 4 5 7 
SCC biopsies 
  Bowen BD MD PD 
Ordered 5 7 10 9 
Excluded 0 2 3 5 
Total 5 5 7 4 
 
 
As seen in table 2, we decided to exclude several biopsies before the beginning of the 
experiment. The biopsies excluded were either too small to see a sufficient quantity of tissue or 
were empty of any cell. 
 
To evaluate TRIP expression in normal skin, we had several paraffin slices from human 
foreskin, scalp, abdomen and face as well as a biopsy from shoulder skin. 
 
The first attempts to perform an IHC on the sections were very unsuccessful with high nuclear 
and cytoplasmic staining, suggesting unspecific binding of the antibody (picture not shown). 
The experimental conditions had to be optimized to get a satisfying result. In particular, the 
primary antibody dilution and incubation time turned out to be crucial to obtain a seemingly 
specific signal. The antigen retrieval was performed by an acidic heat-induced technique. 
However, with some sections, we got better results with a pH 9 antigen retrieval (Tris-EDTA, 
TE).  
 
The results we got were rather heterogeneous and sometimes contradictory. Hence, it was 
quiet challenging to interpret and to summarize them in this work. 
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IHC is a semi-quantitative method, whose interpretation can be addressed by different ways. 
The first question asked is to know if a specific staining is present or not. If so, in what 
percentage of cells is it present, that is to say the extent of staining. Another question concerns 
the intensity of staining. 
 
Those questions can be approached by different methods such as visual scoring systems and 
image analysis by computer software. Visual scoring systems rely on the experience and 
acuity of the eye of the observer and are therefore subject to inter-observer variability (30).  
 
In the literature, data has been showing that image analysis by software can be a suitable 
alternative (31-33) and could as well be time effective (34) and have better sensitivity (35). 
 
In this work, we decided to try both approaches, as shown in sections 2.2.2.1 and 2.2.2.2. 
 
As numerous sections were stained, it’s was not possible to show them all in this work. A 
selection can be seen in figure 9, 10, 11 and 12. Please note that this selection is not clearly 
representative of all slides.   
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Figure 9 – NC: negative control without primary antibody. TE: antigen retrieval by pH 9. INF: infiltrative BCC. NOD: nodular BCC. 
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Figure 10 – NC: negative control without primary antibody. TE: antigen retrieval by pH 9. SCL: sclerosing BCC. SUP: superficial 
BCC. 
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Figure 11 – NC: negative control without primary antibody. BD: well differentiated SCC. 
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Figure 12 – NC: negative control without primary antibody. MD: medium differentiated SCC. PD: well-differentiated SCC. 
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As we can see, there’s a clear nuclear staining pattern with rather low background. In tumor 
tissue, a vast majority of nuclei are stained which suggests that TRIP is extensively present. 
Negative controls with no primary antibody all resulted in negative immunoreactivity. 
In normal skin, staining is absent or almost absent except in the shoulder skin biopsy where 
TRIP expression looks slightly lower than in most tumors tissues, regarding the extent and 
intensity of staining.  
2.2.2.1 Visual score 
We choose to apply a visual score based on the Quick score (37) where proportion of stained 
cells as well as the intensity of staining are taken into consideration. This score works as 
followed: 
Proportion of stained cells: Score Staining intensity: Score 
no nuclear staining 0 no staining 0 
 < 1% nuclear staining 1  weak staining 1 
1-10% nuclear staining 2 moderate staining 2 
11%-60% nuclear staining 3 strong staining 3 
61 – 90 % nuclear staining 4     
90 % - 100% nuclear staining 5     
 
The proportion and the intensity scores are then added. Therefore, minimal score is 1 and 
maximal is 8. Only nuclear staining was considered. A minimum of 100 cells were counted for 
each case. 
Regarding TRIP expression in normal skin, we did analyze the staining in normal skin sections 
(table 6) but also on pieces of normal skin that we identified on tumor slides (table 7). Normal 
skin was not found on each slide. 
Table 3 – Visual score on SCCs 
  Proportion of stained cells Intensity of staining Total score 
Bowen 2 5 3 8 
Bowen 3 5 3 8 
Bowen 4 5 3 8 
Bowen 5 5 3 8 
BD1 5 2 7 
BD2 5 2 7 
BD4 5 2 7 
BD6 4 2 6 
BD7 5 3 8 
MD2 5 2 7 
MD3 4 2 6 
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MD5 4 2 6 
MD7 5 2 7 
MD8 5 2 7 
MD9 5 2 7 
MD10 5 2 7 
PD4 5 2 7 
PD7 5 1 6 
PD8 5 2 7 
PD9 4 1 5 
 
Table 4 – Visual score on BCCs 
  Proportion of stained cells Intensity of staining Total score 
INF1 5 2 7 
INF2 5 3 8 
NOD4 5 2 7 
SCL4 4 2 6 
SCL5 5 2 7 
SCL6 5 2 7 
SUP1 5 2 7 
SUP2 4 1 5 
SUP3 5 2 7 
SUP4 5 3 8 
SUP5 4 2 6 
SUP6 4 3 7 
 
Table 5 – visual score on BCCs retrieved by TE 
  Proportion of stained cells Intensity of staining Total score 
INF4 5 3 8 
INF5 5 3 8 
NOD1 5 2 7 
NOD5 5 3 8 
SUP7 4 2 6 
 
Table 6 – visual score on normal human skin. TE refers to the antigen retrieval method 
  Proportion of stained cells Intensity of staining Total score 
Abdomen 1 2 3 
Shoulder 4 2 6 
Shoulder TE 4 2 6 
Face 1 0 1 
Face TE 2 1 3 
Foreskin  1 0 1 
foreskin TE 1 0 1 
Scalp 1 0 1 
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Table 7 – visual score on normal skin identified in tumor biopsies 
  Proportion of stained cells Intensity of staining Total score 
INF 3 4 1 5 
NOD 4 5 3 8 
SCL 4 5 3 8 
SUP7 4 2 6 
BOW2 5 2 7 
BOW3 5 2 7 
BOW4 4 2 6 
BD1 4 2 6 
BD2 4 1 5 
MD8 5 3 8 
BD4 5 2 7 
BD6 5 2 7 
MD9 5 3 8 
PD1 5 2 7 
 
As we can see, the score of most of the tissues lie between 6 and 8, except in normal skin 
where lower scores are found. However, the normal skin visualized on pieces of tumor has 
similar scores as tumor tissues.  
The proportion of stained cells being very high in almost all tissues, comparison between the 
tissues relies almost completely on the intensity assessment, which is less objective.  
2.2.2.2 Computer assisted image analysis 
Most current imaging systems rely on standard color cameras, employing a red-green-blue 
Bayer-pattern. Those systems distinguish between chromogens present in the picture and do 
unmix them to quantify them separately. In practice, unmixing the DAB brown color from the 
haematoxylin blue color works fine (30). 
However, the color value may vary significantly depending on the camera, the camera chips 
and the illumination source (30). 
 
We choose to use the IHC Profiler, an open-source plugin compatible with Image J (38). This 
plugin can detect either cytoplasmic or nuclear markers. Basically, the IHC profiler works by 
creating a selection in areas with brown pixels. The threshold of pixel detection can be 
manually optimized, so that all nuclei are included in the selection, even the unstained ones. 
The IHC profiler will then undergo a pixel-per-pixel analysis of the selection and the brown 
pixels are divided into 4 categories of intensity: negative, low-positive, positive, high positive.  
 
For this analysis, we selected pieces of picture that did contain high amount of the tissue of 
interest. The selection was then analyzed by IHC profiler.  As with the visual score method, the 
slides that we are comparing were not necessarily stained during the same day but were all 
processed with the same standardized protocol. 
Results are shown in figure 13 and 14. 
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Figure 13 – DAB brown staining is divided into four categories of intensity: negative, low, positive and 
high positive. The vertical axes are showing the percentage of pixels in each category from the total 
pixels in each biopsy.  
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As seen in figure 13, the IHC profiler detects low signal even in the negative control which 
were not showing any staining. This is probably due to a background caused by low quality of 
our pictures. Therefore, we consider that negative and low positive intensity are both 
corresponding to absence of staining. 
The tissues showing the highest proportion of high intensity signal are the Bowen disease, 
which is consistent with their visual score. Interestingly, in SCCs, the lower the degree of 
differentiation, the lower the intensity of the signal. This is also somehow consistent with the 
visual score. 
The intensity pattern is clearly lower in the normal skin compared to tumor tissues. 
However, figure 14 show the intensity pattern of normal skin found on tumors sections and 
there is no clear difference between this pattern and the one from the tumors. 
 
The results obtained with IHC profiler are not to be over interpreted for reasons concerning the 
quality of pictures as well as other limitations that we will discuss next. However, we think that 
it is as useful tool to represent a synthesis of the experiment which contained more than 50 
tissues, allowing a brief overview. 
 
 
2.2.2.3 IHC discussion 
 
The major limitation of IHC is its recurrent lack of reliability and reproducibility which can be 
affected by improper optimization in each step of the experiment.  
A common cited problem is the fixation process. The time necessary for fixation depends on 
size and type of tissue and is often uncontrolled (30). Typically, this can lead to “patchy” 
staining, which we did encounter during the processing of some BCCs sections. 
 
Figure 14 - DAB  brown staining is divided into four categories of intensity: negative, low, positive and 
high positive. The vertical axes are showing the percentage of pixels in each category from the total 
pixels in each biopsy. 
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Another critical step in IHC is the antigen retrieval which can affect both intensity and extend of 
staining. The microwave used for the retrieval in this experiment did not allow a precise control 
of the temperature neither a homogenous heating of the solution containing the slides. This 
may have affected the homogeneity of the results, especially when comparing slides which 
were not stained during the same day. 
  
An important limitation of this experiment was the lack of a proper normal skin control. Indeed, 
all the normal skin tissues we had were inadequately stocked (the shoulder biopsy being an 
exception) and therefore cannot be interpreted. Consequently, we had to search for pieces of 
normal skin in the tumor slides to have something to compare. Those pieces could possibly 
contain molecular defects and are not necessarily completely healthy. 
 
Concerning IHC interpretation, the extent of the staining is easier to assess than the intensity 
which is more subjective. Staining was found in a vast majority of keratinocytes nuclei. 
Therefore, the only way to compare the slides between each other was the intensity of staining 
which makes the interpretation more delicate. In that matter, the IHC profiler turned out to be 
useful. 
 
Ideally, if intensity of staining is being assessed, there should be a positive control, having 
different levels of staining intensity to compare to. Such control was lacking in this work. 
Furthermore, it is important to point out that the intensity of DAB staining is not perfectly 
correlated to the amount of antigen. The relation between both is only linear at low levels of 
antigen (39). However, data suggest that TRIP is expressed at low level (6) which is consistent 
with the high Ct obtained during the real-time PCR. 
 
In this experiment, absence of staining or very low staining was found on the normal skin 
sections except on the shoulder biopsy. This correlates with TRIP mRNA in normal tissue 
reported to be low (6).  However, this absence of staining cannot be interpreted as low 
expression of TRIP in those tissues. Indeed, the slides were cut several years ago. Proteins 
are known to be relatively stable in entire FFPE biopsies but are more sensitive to degradation 
once sliced. Consequently, sections should ideally not be stained more that several months 
after their cutting (36). Therefore, we suspect the absence of staining in the face, foreskin, 
scalp and abdomen tissues to be the consequence of protein degradation by improper 
stocking. Indeed, TRIP staining was quiet strong in normal skin from the shoulder biopsy 
(which was fresh cut) and on pieces of normal skin found on tumor sections.  
Therefore, an important limitation of this experiment was the lack of a proper normal skin 
control. 
 
Altogether, we could not highlight a clear difference in TRIP expression between the different 
tissues. If a difference exists, we are assuming that it is a relative minor one which is difficult to 
assess in a semi-quantitative manner. 
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3 CONCLUSION 
 
The aim of this work was to analyze TRIP expression in BCC and SCC tumors. The measure 
of this expression at mRNA level by real-time PCR did not show interpretable results. 
The IHC experiment seems to have detected TRIP presence in a specific manner and showed 
an extensive expression of TRIP in keratinocytes. Due to numerous limitations related to the 
technique and experiment conditions, it was not possible to determine the relative expression 
of TRIP between tumor and normal skin tissue. 
Consequently, further analyses are needed. The next step could be to perform a real-time 
PCR on new RNA samples. Those samples could be extracted from FFPE biopsies, the latter 
being more easily available than frozen biopsies. To isolate tumor cells from other type of cells, 
laser micro-dissection on FFPE sections prior to the RNA extraction could be considered.  
4 MATHERIAL AND METHOD 
 
Cell culture 
293 T and Hela cells were cultured in DMEM containing 10% fetal bovine serum. 
 
Plasmids 
E. Coli were cultured in a Lysogeny-broth medium containing 100 mg/ml of ampicillin and used 
as a host for the plasmids production. 
 
Plasmid DNA isolation was carried out using QIAGEN Spin Miniprep Kit (QIAGEN) as per the 
manufacturer’s protocol. 
 
Transfections 
293 T cells were transfected in CaCl2 2M and HBSS buffer. 
HeLa cells were transfecting using jetPRIME transfection kit as per the manufacturer protocol. 
 
 
Synthesis of cDNA and real-time PCR 
RNA was purified using the RNeay Kit (Qiagen) and its concentration was measured by 
NanoDrop spectrophotometer. cDNA was synthesized using Primescript-RT Kit (TakaRa). 
Quantitative PCR analysis was performed with Power SYBRGreen PCR Mastermix (Applied 
Biosystems). 
 
Western Blot 
Proteins were extracted by cell lysis in 1% SDS in phosphate-buffered saline and quantified 
using the Pierce BCA Protein Assay Kit. For immunoblots, the following antibodies were used: 
anti-TRAIP antibody (Abcam 151307 and Abcam 4533), anti-rabbit HRP-linked antibody 
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(NA934V, GE healthcare) and anti-goat HRP-linked antibody (sc-2020, Santa Cruz 
Biotechnology). Signal from immunoblots were captured by using LAS4000. 
 
Immunofluorescence 
HeLa cultured cells were fixed with 4% paraformaldehyde. Dako REAL Antibody Diluent was 
used for blocking for 10 minutes at room temperature. Primary antibodies were incubated for 2 
hours at room temperature (anti-TRIP Abcam 151307, anti-TRIP Abcam 4533, anti-FLAG 
Sigma F7425). 
 
 
Immunohistochemistry 
Five µm sections were cut from formalin-fixed, paraffin-embedded tissue block, placed on 
glass slide and dried out at 30° during 3 hours. Sections were deparaffinized in xylene and 
rehydrated in ascending grades of alcohol. Antigen retrieval was performed in pH 6 Citrate 
buffer 1M at 95° for 15 minutes, using a microwave. In some cases, pH 9 Tris 10 mM-EDTA 
1,26 mM at 95° during 20 minutes was preferred. Endogenous peroxidase activity was 
exhausted by incubation of tissue sections in 3% hydroxide peroxide for 10 minutes. 2,5% 
ready-to use horse serum from ImmPRESS anti-rabbit (Vector laboratories) was used for 
blocking. The primary antibody was the Abcam 151307. It was diluted at 1:1500 in 2,5 % 
ready-to-use horse serum at room temperature for 1 hour. Slides were then incubated with a 
ready to use secondary antibody (ImmPRESS anti-rabbit, Vector laboratories) for 30 minutes 
at room temperature. The antigen-antibody complex was visualized with the chromogen DAB 
which was incubated for 5 minutes and counterstained with hematoxylin. All tissue sections 
were stained under similar conditions to ensure equal staining quality. A negative control was 
performed in all cases by omitting the primary antibody, which in all instances resulted in 
negative immunoreactivity. 
Pictures were taken by AxioCam and AxioVision software 4.8. Images were analyzed by 
ImageJ and IHC Profiler. 
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